Lilly and Banner Alzheimer's Institute collaborate on planned Phase 3 prevention trial of donanemab

Trial will include participants at risk for cognitive and functional decline related to Alzheimer's disease INDIANAPOLIS and PHOENIX , July 15, 2021 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and Banner Alzheimer's Institute today announced a strategic research collaboration as part of the